Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist

被引:150
作者
Rizzo, Giovanni [1 ]
Passeri, Daniela [1 ]
De Franco, Francesca [1 ]
Ciaccioli, Gianmario [1 ]
Donadio, Loredana [1 ]
Rizzo, Giorgia [1 ]
Orlandi, Stefano [1 ]
Sadeghpour, Bahman [1 ]
Wang, Xiaoxin X. [2 ]
Jiang, Tao
Levi, Moshe [2 ]
Pruzanski, Mark [3 ]
Adorini, Luciano [1 ]
机构
[1] Intercept Pharmaceut, I-06073 Perugia, Italy
[2] Univ Colorado, Dept Med, Denver, CO USA
[3] Intercept Pharmaceut, New York, NY USA
基金
美国国家卫生研究院;
关键词
NUCLEAR RECEPTOR; FXR; IDENTIFICATION; ACTIVATION; ADIPOCYTE; PROMOTER; LIGANDS; SHP;
D O I
10.1124/mol.110.064501
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two dedicated receptors for bile acids (BAs) have been identified, the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, which represent attractive targets for the treatment of metabolic and chronic liver diseases. Previous work characterized 6 alpha-ethyl-3 alpha, 7 alpha-dihydroxy-5 beta-cholan-24-oic acid (INT-747), a potent and selective FXR agonist, as well as 6 alpha-ethyl-23(S)-methyl-3 alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholan-24-oic acid (INT-777), a potent and selective TGR5 agonist. Here we characterize 6 alpha-ethyl-3 alpha, 7 alpha, 23-trihydroxy-24-nor-5 beta-cholan-23-sulfate sodium salt (INT-767), a novel semisynthetic 23-sulfate derivative of INT-747. INT-767 is a potent agonist for both FXR (mean EC50, 30 nM by PerkinElmer AlphaScreen assay) and TGR5 (mean EC50, 630 nM by time resolved-fluorescence resonance energy transfer), the first compound described so far to potently and selectively activate both BA receptors. INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel. In line with its dual activity, INT-767 induces FXR-dependent lipid uptake by adipocytes, with the beneficial effect of shuttling lipids from central hepatic to peripheral fat storage, and promotes TGR5-dependent glucagon-like peptide-1 secretion by enteroendocrine cells, a validated target in the treatment of type 2 diabetes. Moreover, INT-767 treatment markedly decreases cholesterol and triglyceride levels in diabetic db/db mice and in mice rendered diabetic by streptozotocin administration. Collectively, these preclinical results indicate that INT-767 is a safe and effective modulator of FXR and TGR5-dependent pathways, suggesting potential clinical applications in the treatment of liver and metabolic diseases.
引用
收藏
页码:617 / 630
页数:14
相关论文
共 43 条
[1]   Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor [J].
Ananthanarayanan, M ;
Balasubramanian, N ;
Makishima, M ;
Mangelsdorf, DJ ;
Suchy, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :28857-28865
[2]   The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice [J].
Cariou, B ;
van Harmelen, K ;
Duran-Sandoval, D ;
van Dijk, TH ;
Grefhorst, A ;
Abdelkarim, M ;
Caron, S ;
Torpier, G ;
Fruchart, JC ;
Gonzalez, FJ ;
Kuipers, F ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) :11039-11049
[3]   FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats [J].
Cipriani, Sabrina ;
Mencarelli, Andrea ;
Palladino, Giuseppe ;
Fiorucci, Stefano .
JOURNAL OF LIPID RESEARCH, 2010, 51 (04) :771-784
[4]   Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase promoter by nuclear receptors liver receptor homologue-1 and small heterodimer partner - A mechanism for differential regulation of cholesterol synthesis and uptake [J].
Datta, S ;
Wang, L ;
Moore, DD ;
Osborne, TF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (02) :807-812
[5]   A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia [J].
Evans, Mark J. ;
Mahaney, Paige E. ;
Borges-Marcucci, Lisa ;
Lai, KehDih ;
Wang, Shuguang ;
Krueger, Julie A. ;
Gardell, Stephen J. ;
Huard, Christine ;
Martinez, Robert ;
Vlasuk, George P. ;
Harnish, Douglas C. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 296 (03) :G543-G552
[6]   Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts [J].
Fickert, Peter ;
Fuchsbichler, Andrea ;
Moustafa, Tarek ;
Wagner, Martin ;
Zollner, Gernot ;
Halilbasic, Emina ;
Stoeger, Ulrike ;
Arrese, Marco ;
Pizarro, Margarita ;
Solis, Nancy ;
Carrasco, Gonzalo ;
Caligiuri, Alessandra ;
Sombetzki, Martina ;
Reisinger, Emil ;
Tsybrovskyy, Oleksiy ;
Zatloukal, Kurt ;
Denk, Helmut ;
Jaeschke, Hartmut ;
Pinzani, Massimo ;
Trauner, Michael .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (06) :2392-2405
[7]   The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis [J].
Fiorucci, S ;
Antonelli, E ;
Rizzo, G ;
Renga, B ;
Mencarelli, A ;
Riccardi, L ;
Orlandi, S ;
Pellicciari, R ;
Morelli, A .
GASTROENTEROLOGY, 2004, 127 (05) :1497-1512
[8]   Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes [J].
Fu, L ;
John, LM ;
Adams, SH ;
Yu, XX ;
Tomlinson, E ;
Renz, M ;
Williams, PM ;
Soriano, R ;
Corpuz, R ;
Moffat, B ;
Vandlen, R ;
Simmons, L ;
Foster, J ;
Stephan, JP ;
Tsai, SP ;
Stewart, TA .
ENDOCRINOLOGY, 2004, 145 (06) :2594-2603
[9]   The Adipocyte as an Endocrine Cell [J].
Halberg, Nils ;
Wernstedt-Asterholm, Ingrid ;
Scherer, Philipp E. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (03) :753-+
[10]   Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice [J].
Hartman, Helen B. ;
Gardell, Stephen J. ;
Petucci, Chris J. ;
Wang, Shuguang ;
Krueger, Julie A. ;
Evans, Mark J. .
JOURNAL OF LIPID RESEARCH, 2009, 50 (06) :1090-1100